Multiple advocacy groups went straight to the top of a still undecided FDA to advocate against loosening conflict of interest rules for advisory committees.
The December meeting between FDA Commissioner Margaret Hamburg and members of the Patient, Consumer and Public Health Coalition allowed the advocates to express their concerns about what they perceive as FDA eagerness to modify the conflict of interest rules